Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
The DOI matches its Crossref record.
Abstract
3515 Background: BRAF V600 mutations occur in 5–10% of CRC and confer poor prognosis. Unlike in BRAF mutant (BRAFm) melanoma, BRAF and MEK inhibitors show limited activity in BRAFm CRC. Preclinical data suggest that EGFR can mediate resistance in BRAFm CRC, which can be overcome by combined inhibition of BRAF and EGFR. Therefore, combined inhibition of the BRAF pathway (with D or D + T and with anti-EGFR agent P) to prevent EGFR-mediated resistance is a rational and promising approach to treat BRAFm CRC. Methods: Eligible pts with BRAFm CRC enrolled in Parts 1 and 2 of the ongoing 3-part study, dose escalation (DE; Part 1), cohort expansion (CE; Part 2) and a planned randomized comparison (Part 3), received either the doublet (D + P) or triplet (D + P + T) combination. Results: 19 pts received D + P ± T in DE or CE. Doublet: 6 pts received the full doublet dose (D 150 mg twice daily [BID] + P 6 mg/kg every 2 weeks [Q2W]) in Cohort 1 DE and 3 pts received the doublet in Part 2 CE. Triplet: 3 pts received the lowest combination dose of the triplet (D 150 mg BID + P 4.8 mg/kg Q2W + T 1.5 mg once daily [QD]) in Cohort 2. DE Cohorts 3A (D 150 mg BID + P 4.8 mg/kg Q2W + T 2 mg QD), n = 4 and 3B (D 150 mg BID + P 6 mg/kg Q2W + T 1.5 mg QD), n = 3 were opened simultaneously. No dose-limiting toxicities have been seen in any cohorts. Most common drug-related adverse event (AE) was dermatitis acneiform for doublet (5/9 pts, all Grade [Gr] 1) and triplet (5/10 pts, 3 Gr 1 and 2 Gr 2) pts. In the doublet group, no possibly drug-related Gr > 3 events were reported. In the triplet group, Gr > 3 events at least possibly drug-related, included vomiting (n = 1), rash (n = 1) and skin fissures (n = 1). In preliminary efficacy data, partial responses have been seen in 4/6 evaluable pts on the triplet dose (3/4 ongoing, 1 > 7 months) with 2 pts with stable disease (SD; 1 ongoing and 1 discontinued due to AE). Of the 8 evaluable pts on the doublet dose, 7/8 achieved SD (lasting 6–26 weeks; 2 pts ongoing) as the best overall response. Updated results will be presented. Conclusions: P can be safely combined with D or D/T. Encouraging evidence of clinical activity has been seen. Clinical trial information: NCT01750918.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Small molecules, big impact: 20 years of targeted therapy in oncology
Bedard, P. L., Hyman, D. M., Davids, M. S., & Siu, L. L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30164-1 · Cited by 610
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322
Self-citationYaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
Metadata
- Authors
- Bendell, J. C., Atreya, C. E., André, T., Tabernero, J., Gordon, M. S., Bernards, R., Van Cutsem, E., Tejpar, S., Sidhu, R., Go, W. Y., Allred, A., Motwani, M., Suttle, B. B., Wu, Y., Hoos, A., Orford, K. W., Corcoran, R. B., & Schellens, J. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-05-20
- Volume
- 32
- Issue
- 15_suppl
- Pages
- 3515-3515
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2472619494
- Cited by
- 63
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.3515
- The paper
- Bendell, J. C., Atreya, C. E., André, T., Tabernero, J., Gordon, M. S., Bernards, R., Van Cutsem, E., Tejpar, S., Sidhu, R., Go, W. Y., Allred, A., Motwani, M., Suttle, B. B., Wu, Y., Hoos, A., Orford, K. W., Corcoran, R. B., & Schellens, J. H. (2014). Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.3515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.